Table 3.
DST performance and TB drug use among patients with MDR-TB (N = 105)
| 3a: N (%) of patients who had DST performed per drug up to the indicated time point among those under follow-up at given time point |
||||||||||||||
| N | R | H | Z | E | FQ | 2L-inj | PT/ET | CS/TZ | PAS | BDQ | DLM | LNZ | ||
| 0 | 105 | 49 (47) | 49 (47) | 27 (26) | 46 (44) | 35 (33) | 37 (35) | 32 (30) | 16 (15) | 24 (23) | 0 | 0 | 0 | |
| 1 month | 88 | 88 (100) | 88 (100) | 47 (53) | 82 (93) | 63 (72) | 66 (75) | 57 (65) | 40 (45) | 47 (53) | 0 | 0 | 0 | |
| 2 months | 79 | 79 (100) | 79 (100) | 44 (56) | 74 (94) | 58 (73) | 64 (81) | 54 (68) | 40 (51) | 45 (57) | 0 | 0 | 0 | |
| 3 months | 72 | 72 (100) | 72 (100) | 40 (56) | 68 (94) | 54 (75) | 61 (85) | 51 (71) | 37 (51) | 41 (57) | 0 | 0 | 0 | |
| 7 months | 56 | 56 (100) | 56 (100) | 42 (57) | 53 (95) | 43 (77) | 47 (84) | 40 (71) | 30 (54) | 33 (59) | 0 | 0 | 0 | |
| 13 months | 44 | 44 (100) | 44 (100) | 25 (57) | 42 (95) | 35 (80) | 37 (84) | 30 (70) | 22 (50) | 26 (59) | 0 | 0 | 0 | |
| 21 months | 31 | 31 (100) | 31 (100) | 16 (52) | 29 (94) | 23 (74) | 25 (81) | 23 (74) | 16 (52) | 22 (71) | 0 | 0 | 0 | |
| 3b: N (%) of patients under follow-up who received selected anti-TB medications at the indicated time point |
||||||||||||||
| N | R | H | Z | E | FQ | 2L-inj | PT/ET | CS/TZ | PAS | BDQ | DLM | LNZ | ||
| 0 | 105 | 86 (82) | 89 (85) | 90 (86) | 84 (80) | 16 (15) | 23 (22) | 14 (13) | 10 (10) | 4 (4) | 0 | 0 | 0 | |
| 1 month | 88 | 57 (65) | 59 (67) | 76 (86) | 68 (77) | 32 (36) | 38 (43) | 31 (35) | 23 (26) | 17 (19) | 0 | 0 | 0 | |
| 2 months | 79 | 39 (49) | 37 (47) | 66 (84) | 53 (67) | 43 (54) | 46 (58) | 40 (51) | 30 (38) | 29 (34) | 0 | 0 | 0 | |
| 3 months | 72 | 23 (32) | 23 (32) | 55 (76) | 37 (51) | 51 (71) | 48 (67) | 49 (68) | 39 (54) | 33 (46) | 0 | 0 | 0 | |
| 7 months | 56 | 6 (11) | 5 (9) | 42 (75) | 21 (38) | 50 (89) | 39 (70) | 47 (84) | 37 (66) | 31 (55) | 0 | 0 | 1 (2) | |
| 13 months | 44 | 5 (11) | 4 (9) | 34 (77) | 14 (32) | 39 (89) | 15 (34) | 33 (75) | 27 (61) | 20 (45) | 0 | 0 | 0 | |
| 21 months | 31 | 2 (6) | 1 (3) | 20 (65) | 7 (23) | 25 (81) | 8 (26) | 19 (61) | 22 (71) | 15 (48) | 0 | 0 | 0 | |
| 3c: N (%) of patients under follow-up who had ever received selected TB medications at the indicated time point |
||||||||||||||
| N | R | H | Z | E | FQ | 2L-inj | PT/ET | CS/TZ | PAS | BDQ | DLM | LNZ | ||
| 0 | 105 | 86 (82) | 89 (85) | 90 (86) | 84 (80) | 16 (15) | 23 (22) | 14 (13) | 10 (10) | 4 (4) | 0 | 0 | 0 | |
| 1 month | 88 | 76 (86) | 75 (85) | 81 (92) | 76 (86) | 33 (38) | 40 (45) | 32 (36) | 23 (26) | 17 (19) | 0 | 0 | 0 | |
| 2 months | 79 | 68 (86) | 66 (84) | 72 (91) | 68 (86) | 45 (60) | 49 (62) | 41 (52) | 31 (39) | 29 (37) | 0 | 0 | 0 | |
| 3 months | 72 | 62 (86) | 61 (85) | 66 (92) | 61 (85) | 54 (75) | 55 (76) | 51 (71) | 40 (56) | 36 (50) | 0 | 0 | 0 | |
| 7 months | 56 | 47 (84) | 47 (84) | 53 (95) | 51 (91) | 51 (91) | 49 (88) | 48 (86) | 40 (71) | 33 (59) | 0 | 0 | 1 (2) | |
| 13 months | 44 | 39 (89) | 39 (89) | 42 (95) | 42 (95) | 40 (91) | 38 (86) | 37 (84) | 31 (70) | 24 (55) | 0 | 0 | 0 | |
| 21 months | 31 | 27 (87) | 27 (87) | 29 (94) | 30 (97) | 29 (94) | 28 (90) | 26 (84) | 23 (74) | 20 (65) | 0 | 0 | 0 | |
DST: Drug Susceptibility Test; R: Rifampicin; H: Isoniazid; Z: Pyrazinamide; E: Ethambutol; FQ: Fluoroquinolone; 2L-inj: Second-line injectables; PT/ET: Prothionamide/Ethionamide; CS/TZ: Cycloserine/Terizidone; PAS: Para-aminosalicylic acid; BDQ: Bedaquiline; DLM: Delamanide; LNZ: Linezolid.